Printer Friendly

RUSSIAN DOCTORS TO COORDINATE USE OF MOSCOW RESEARCH LABORATORIES FOR ALZHEIMER'S DISEASE STUDIES

 NEWPORT BEACH, Calif., Dec. 15 /PRNewswire/ -- Spectrum Pharmaceutical Corp. of Newport Beach said it has recently signed employment contracts with two Russian doctors to coordinate the use of existing Russian research facilities for projects of Spectrum Pharmaceutical Corp. as well as other companies and institutions.
 According to Dr. Howard Wertheim, president of Spectrum Pharmaceutical Corp., science was a top priority under former Soviet leadership, but the lack of funding to pay highly trained doctors and researchers has left these professionals with little work and has threatened to close many research laboratories.
 An Alzheimer's Disease joint research project is being explored between Spectrum Pharmaceutical Corp. and the University of California, Irvine, which would be one of the first efforts.
 A UCI researcher, Dr. Charles Glabe, has developed a new laboratory testing procedure that could identify a drug that would inhibit or eliminate formation on brain cells of beta amyloid protein aggregation, which it is now believed to be a major cause of the symptoms of Alzheimer's Disease.
 Since hundreds of thousands of chemical compounds and drugs may need to be tested and evaluated to find ones that will be effective in Alzheimer's Disease, the costs of the project in the United States would be extremely high, whereas in Russia the same high-quality research can be done at a fraction of the cost and in a much shorter time.
 -0- 12/15/92
 /CONTACT: Dr. Howard I. Wertheim, president of Spectrum Pharmaceutical, 714-854-7100/


CO: Spectrum Pharmaceutical Corp. ST: California IN: MTC SU:

MS-JL -- LA002 -- 4685 12/15/91 13:01 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 3, 1992
Words:259
Previous Article:HARRIS WINS $35 MILLION SATELLITE COMMUNICATIONS CONTRACT
Next Article:TOYOTA SALES RISE 32 PERCENT IN FIRST 10-DAY PERIOD OF DECEMBER
Topics:


Related Articles
SIBIA REPORTS SUCCESS OF ALZHEIMER'S DIAGNOSTIC ASSAY
WYETH-AYERST FUNDS $16 MILLION WHI ALZHEIMER'S DISEASE TRIAL STUDYING HORMONE REPLACEMENT THERAPY
Wyeth-Ayerst is Sole Supplier of Product for First International Study To Evaluate HRT Benefits
Two Studies Show Potential Effects of Investigational Alzheimer's Drug.
Forest Laboratories, Developer of Investigational Alzheimer's Therapy, Sponsors Scientific Session at 10th Annual National Alzheimer's Disease...
Alzheimer's Disease Immunotherapeutic to Advance to Exploratory Phase 2A Studies.
ALZHEIMER'S DISEASE IMMUNOTHERAPEUTIC TO ADVANCE TO EXPLORATORY PHASE 2A STUDIES.
Data on Forest Laboratories' Investigational Alzheimer's Disease Treatment Will be Presented at 15th American Association For Geriatric Psychiatry...
Elan and Wyeth Provide Update on Status of Alzheimer's Collaboration.
New Study Shows Improved Cognition Relative to Baseline for Alzheimer's Patients Treated With Investigational Memantine and Donepezil.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters